Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)

Caroline M. Robb, Jacob I. Contreras, Smit Kour, Margaret Taylor, Mohammad Abid, Yogesh A. Sonawane, Muhammad Zahid, Daryl J. Murry(Susan Thompson Buffett Foundation), Amarnath Natarajan(Susan Thompson Buffett Foundation), Sandeep Rana
Chemical Communications
January 1, 2017
10.1039/c7cc03879h
Cited by 208

Abstract

Cyclin-dependent kinase 9 (CDK9), a member of the cyclin-dependent protein kinase (CDK) family, is involved in transcriptional elongation of several target genes. CDK9 is ubiquitously expressed and has been shown to contribute to a variety of malignancies such as pancreatic, prostate and breast cancers. Here we report the development of a heterobifunctional small molecule proteolysis targeting chimera (PROTAC) capable of cereblon (CRBN) mediated proteasomal degradation of CDK9. In HCT116 cells, it selectively degrades CDK9 while sparing other CDK family members. This is the first example of a PROTAC that selectively degrades CDK9.

Related Papers

Phthalimide conjugation as a strategy for in vivo target protein degradation
Georg E. Winter, Dennis L. Buckley, Joshiawa Paulk et al.|Science|2015|1.7k
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
Ashley R. Schneekloth, Mathieu Pucheault, Hyun Seop Tae et al.|Bioorganic & Medicinal Chemistry Letters|2008|597
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Lawrence M. Gelbert, Shufen Cai, Xi Lin et al.|Investigational New Drugs|2014|564
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia
John C. Byrd, Thomas S. Lin, James T. Dalton et al.|Blood|2006|388
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Julia A. Beaver, Laleh Amiri‐Kordestani, Rosane Charlab et al.|Clinical Cancer Research|2015|371